Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Erasca Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Erasca şirketinin toplam hissedar öz sermayesi $451.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $525.7M ve $74.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$408.41m
Eşitlik	US$451.09m
Toplam yükümlülükler	US$74.66m
Toplam varlıklar	US$525.74m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Recent updates

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ERAS 'nin kısa vadeli varlıkları ( $418.0M ) kısa vadeli yükümlülüklerini ( $24.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: ERAS şirketinin kısa vadeli varlıkları ( $418.0M ) uzun vadeli yükümlülüklerini ( $49.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ERAS borçsuzdur.

Borcun Azaltılması: ERAS son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ERAS şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: ERAS serbest nakit akışı her yıl % 20 2.3 yıl yetecek nakit akışına sahip olacaktır.

Erasca Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Recent updates

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin